ACE Inhibitor Selection and Management in Cardiovascular Disease

Introduction to ACE Inhibitors

The American College of Cardiology (ACC) and American Heart Association (AHA) recommend using captopril, enalapril, lisinopril, or ramipril at target doses proven in clinical trials for heart failure with reduced ejection fraction and post-myocardial infarction, as these four agents have the strongest evidence for reducing mortality and morbidity 1, 2

The ACC/AHA guidelines specifically identify four ACE inhibitors with proven mortality benefit in landmark trials: captopril, enalapril, lisinopril, and ramipril, with recommended initial and target doses 1, 2
Captopril should be initiated at 6.25 mg three times daily and titrated to 50 mg three times daily 1, 2, 3
Enalapril should be initiated at 2.5 mg twice daily and titrated to 10-20 mg twice daily 1, 2
Lisinopril should be initiated at 2.5-5 mg once daily and titrated to 20-40 mg once daily 1, 2, 4
Ramipril should be initiated at 1.25-2.5 mg once daily and titrated to 10 mg once daily 1, 2

High-dose lisinopril (32.5-35 mg/day) demonstrated significantly lower mortality compared to low-dose lisinopril (2.5-5 mg/day) in the ATLAS trial, emphasizing the importance of titrating to target doses 5
Ramipril reduced relative mortality risk by 27% overall in post-MI patients with LV dysfunction, with a 41% reduction specifically in hypertensive patients 5
Trandolapril showed a 7% absolute mortality reduction in the TRACE trial 5

ACE inhibitors are first-line therapy for diabetic patients with microalbuminuria or clinical nephropathy 6
The MICRO-HOPE study demonstrated cardiovascular benefits with ramipril that may extend beyond blood pressure reduction alone 6

Start with low doses and titrate to target doses used in clinical trials, particularly in patients at risk for hypotension 1, 2, 3, 4
Double doses at each titration step, monitoring blood pressure, renal function, and potassium within 1-2 weeks after each change 2, 3, 4, 5

Monitor for ACE inhibitor-related adverse effects, including hypotension, worsening renal function, hyperkalemia, cough, and angioedema 1, 2, 4, 5
Never exceed the maximum recommended dose of 40 mg once daily for lisinopril; if blood pressure control is inadequate, add a different antihypertensive class rather than exceeding maximum doses 4

If ACE inhibitors cause intolerable cough or angioedema, candesartan and valsartan have demonstrated equivalent mortality and hospitalization benefits 1, 2